1. Introduction
Infectious diseases pose continuous and increasing risks to human health and welfare along with the development of human society [1]. Even nowadays, in the twenty-first century when individuals, communities, and hospitals have easy access to effective disinfectants, abundant antibiotics, and advanced medical technologies, infectious disease outbreaks are still able to cause severe consequences on lives and livelihoods all over the world [2]. In fact, according to a recent comprehensive demographic analysis for the Global Burden of Disease Study, around seven million people died of infectious diseases in 2019, representing approximately 12% of all deaths globally [3]. As one of the five major infectious agents, that is, viruses, bacteria, fungi, protozoa, and helminths [4], bacteria have a significant impact on public health since their infections can occur at any part of human body and can be transmitted to human beings
2. Bacterial biofilm formation and regulation
In specificity, bacterial biofilm is a highly complex, well-organized, three-dimension-structural consortium of bacteria that are embedded in a self-produced extracellular matrix, containing polysaccharides, proteins and nucleic acids, and so on [10]. Despite the structural complexity of bacterial biofilms, a classical five-step model was previously proposed to explain its formation: (1) reversible attachment phase, (2) irreversible attachment phase, (3) extracellular polymeric substances (EPS) production, (4) maturation, and (5) dispersal and detachment [11]. Recently, Sauer et al. have revised the conceptual model and proposed a simple three-step biofilm formation model, that is, aggregation, growth, and disaggregation, in order to represent a broader range of biofilm system [12]. Biofilm formation is sophisticatedly regulated and is involved in complex network of regulatory cascades such as quorum sensing (QS) system (communications of bacterial cells within biofilm), regulatory small RNAs (sRNAs), second messengers (cyclic-di-guanosine monophosphate, c-di-GMP), and so forth [13], while elucidation of the regulatory mechanisms of biofilm formation will promote the development of effective strategies to biofilm inhibition and control [14].
3. Bacterial biofilm prevention, inhibition, and eradication
Biofilm infections are persistent and recalcitrant, are tightly associated with the rise of antibiotic resistance, and show heterogeneous features with diverse nature [15]. Due to the harmfulness of bacterial biofilms in human infections, effective strategies for preventing, inhibiting, and eradicating biofilms are urgently needed. As the proverb runs, prevention is better than cure [16]. Therefore, it is always the priority to prevent the formation of bacterial biofilm rather than to inhibit and eradicate it, which requires less effort on biofilm control. Multiple strategies are currently available for biofilm prevention, which most frequently involve treating abiotic surfaces (smoothness, wettability, or hydrophilicity) and coating surfaces (salivary proteins, 2-methacryloyloxyethyl phosphorylcholine, monomeric trimethylsilane, antimicrobial peptide) [17]. These methods are able to greatly reduce microbial attachment to device surface, hence preventing biofilm formation and reducing bacterial infection. As for the inhibition of bacterial biofilms, there are also many effective combating tactics like quorum-sensing blockage, hindering the biosynthesis of N-acyl-homoserine lactones (AHL) signal molecule, biodegradation or alteration of AHL signal molecule, interference with receptor proteins by analog compounds, and so on [18]. Further in-depth studies are needed to elucidate the effects and mechanisms of these biofilm inhibition tactics so that they could be used in the host, proving their applicability to humans in clinical settings. Although prevention and inhibition of bacterial biofilms provide some clinical premise, these methods do not represent a direct treatment for established biofilms while eradication agents and approaches are efficient to remove mature biofilms [19]. Several representative methods include electrochemical methods, antimicrobial compounds, biofilm architecture modulation, and drug delivery methods, all of which aim to eradicate bacterial biofilms when applied alone or synergistically [20]. However, the eradication of mature bacterial biofilms is extraordinarily difficult. More strategies and novel compounds need to be developed for a more effective fight against biofilms.
4. Summary
With the development of prevention, inhibition, and eradication methods of bacterial biofilms, the mortality rate of chronic and fatal bacterial infections is expected to be greatly reduced in future.
Acknowledgments
This study was financially supported by Research Foundation for Advanced Talents of Guandong Provincial People’s Hospital [Grant No. KY012023293].
Author contributions
LW and BG conceived the framework of the manuscript, provided platform and resources, and contributed to project administration and funding acquisitions. All the authors contributed to the writing and revision of the manuscript and approved the submission of the final version of the manuscript.
Declaration of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Inclusion and diversity
We support inclusive, diverse, and equitable conduct of research.
References
- 1.
Becker K, Hu Y, Biller-Andorno N. Infectious diseases – A global challenge. International Journal of Medical Microbiology. 2006; 296 :179-185 - 2.
Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, et al. Infectious disease in an era of global change. Nature Reviews Microbiology. 2021; 20 :193-205 - 3.
Wang H, Abbas KM, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, et al. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: A comprehensive demographic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020; 396 :1160-1203 - 4.
Drexler M. What you Need to Know about Infectious Disease. Washington (DC): National Academies Press (US); 2011 - 5.
Doron S, Gorbach SL. Bacterial infections: Overview. In: International Encyclopedia of Public Health. Academic Press; 2008. pp. 273-282 - 6.
Sakai T, Morimoto Y. The history of infectious diseases and medicine. Pathogens. 2022; 11 :1-12 - 7.
Aminov RI. A brief history of the antibiotic era: Lessons learned and challenges for the future. Frontiers in Microbiology. 2010; 1 :1-7 - 8.
Uruén C, Chopo-Escuin G, Tommassen J, Mainar-Jaime RC, Arenas J. Biofilms as promoters of bacterial antibiotic resistance and tolerance. Antibiotics. 2020; 10 :1-36 - 9.
Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS. 2013; 121 :1-58 - 10.
Høiby N, Ciofu O, Johansen HK, Song ZJ, Moser C, Jensen PØ, et al. The clinical impact of bacterial biofilms. International Journal of Oral Science. 2011; 3 :55-65 - 11.
Muhammad MH, Idris AL, Fan X, Guo Y, Yu Y, Jin X, et al. Beyond risk: Bacterial biofilms and their regulating approaches. Frontiers in Microbiology. 2020; 11 :1-20 - 12.
Sauer K, Stoodley P, Goeres DM, Hall-Stoodley L, Burmølle M, Stewart PS, et al. The biofilm life cycle: Expanding the conceptual model of biofilm formation. Nature Reviews Microbiology. 2022; 20 :608-620 - 13.
Schulze A, Mitterer F, Pombo JP, Schild S. Biofilms by bacterial human pathogens: Clinical relevance—Development, composition and regulation—Therapeutical strategies. Microbial Cell. 2021; 8 :28-56 - 14.
Samrot AV, Abubakar Mohamed A, Faradjeva E, Si Jie L, Hooi Sze C, Arif A, et al. Mechanisms and impact of biofilms and targeting of biofilms using bioactive compounds—A review. Medicina. 2021; 57 :1-28 - 15.
Da Silva RAG, Afonina I, Kline KA. Eradicating biofilm infections: An update on current and prospective approaches. Current Opinion in Microbiology. 2021; 63 :117-125 - 16.
Borysiewicz L. Prevention is better than cure. Clinical Medicine. 2009; 9 :572-583 - 17.
Yin W, Xu S, Wang Y, Zhang Y, Chou S-H, Galperin MY, et al. Ways to control harmful biofilms: Prevention, inhibition, and eradication. Critical Reviews in Microbiology. 2020; 47 :57-78 - 18.
Srinivasan R, Santhakumari S, Poonguzhali P, Geetha M, Dyavaiah M, Xiangmin L. Bacterial biofilm inhibition: A focused review on recent therapeutic strategies for combating the biofilm mediated infections. Frontiers in Microbiology. 2021; 12 :1-19 - 19.
Verderosa AD, Totsika M, Fairfull-Smith KE. Bacterial biofilm eradication agents: A current review. Frontiers in Chemistry. 2019; 7 :1-17 - 20.
Wolfmeier H, Pletzer D, Mansour SC, Hancock REW. New perspectives in biofilm eradication. ACS Infectious Diseases. 2017; 4 :93-106